Patent · US Expired

Methods for treating cancer using PSCA antibodies and fragments thereof

US6756036B2 · kind B2 · utility

18Cited by
2References
28Claims
0Family size

Assignees

Inventors

Key dates

Filing dateSep 26, 2001
Grant dateJun 29, 2004
Priority date
Expiry dateNov 19, 2021

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/705
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.